Translational findings support regimen selection for first‐in‐human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer
Min Zhu, Priyanka Madia, Alison Crawford, Jurriaan Brouwer‐Visser, Pamela Krueger, Lauric Haber, Mary Peterman, Thomas S Uldrick, Elizabeth Miller, John D Davis, Marc W Retter · 2024
Read Translational findings support regimen selection for first‐in‐human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer by Min Zhu, Priyanka Madia, Alison Crawford, Jurriaan Brouwer‐Visser, Pamela Krueger, Lauric Haber, Mary Peterman, Thomas S Uldrick, Elizabeth Miller, John D Davis, Marc W Retter (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11627180.txt.
Description
Eleven researchers choose a dosing plan for a first human trial of an ovarian cancer antibody in a paper from 2024. The drug, ubamatamab, links T cells to a marker found on ovarian tumors. Lab tests measured cell killing and immune signals. Monkey data scaled into predicted human drug levels. Mouse tumor studies set the concentration range where the drug works.
A starting dose of a tenth of a milligram proved acceptably safe in patients. Step-up dosing tamed the immune reaction syndrome that followed. Clinical activity matched levels predicted from the mouse work. The team settled on target blood levels and two expansion regimens, with or without a second immune drug. The study shows preclinical data guiding trial design.
Catalog record
| CREATOR | Min Zhu, Priyanka Madia, Alison Crawford, Jurriaan Brouwer‐Visser, Pamela Krueger, Lauric Haber, Mary Peterman, Thomas S Uldrick, Elizabeth Miller, John D Davis, Marc W Retter |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |